Targeting the gut-liver axis in liver disease

Journal of Hepatology

Volumn 67, Issue 5, 2017, Pages 1084-1103

  Wiest, Reiner ^a   Albillos, Agustin ^b   Trauner, Michael ^c   Bajaj, Jasmohan S ^d   Jalan, Rajiv ^e  

^a UNIVERSITY OF BERN   (Switzerland)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bacterial translocation; Bile acids; Cirrhosis; Faecal microbial transplantation; Fibrosis; Gut liver axis; Incretines; Liver injury; Microbiome; Pre , probiotics

Indexed keywords

ACTIVATED CARBON; ADSORBENT; ANTIBIOTIC AGENT; AST 120; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CILOFEXOR; CIPROFLOXACIN; CISAPRIDE; COLESTYRAMINE; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LACTULOSE; LIRAGLUTIDE; NEOMYCIN; NORFLOXACIN; PAROMOMYCIN; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN; SELONSERTIB; SEROTONIN; SITAGLIPTIN; SYNBIOTIC AGENT; VANCOMYCIN; VOLIXIBAT;

ALCOHOL LIVER DISEASE; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BARIATRIC SURGERY; BODY MASS; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); DECOMPENSATED LIVER CIRRHOSIS; DRUG ABSORPTION; DRUG EFFICACY; DYSBIOSIS; FATTY LIVER; FECAL MICROBIOTA TRANSPLANTATION; GUT LIVER AXIS; HEPATIC ENCEPHALOPATHY; HORMONE RELEASE; HUMAN; INTESTINE; INTESTINE FLORA; INTRAHEPATIC CHOLESTASIS; LIVER; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LIVER SINUSOID; LIVER STIFFNESS; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERISTALSIS; PRIORITY JOURNAL; REVIEW; DISEASE MANAGEMENT; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES;

DISEASE MANAGEMENT; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER DISEASES;

EID: 85028513404     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.05.007     Document Type: Review

References (229)

1. Cani, P.D., Amar, J., Iglesias, M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
2. Suriguga, Su, Luangmonkong, Theerut, Bigaeva, Emilia, Oosterhuis, Dorenda, Mutsaers, Henricus A.M., Groothuis, Geny M., et al. LPS aggravates fibrosis only in the early onset but not in the end stage of liver fibrosis. Hepatology, 64, 2016, 840A.
3. Hiroki Utsunomiya YY, Eiji Takeshita, Yoshio, Tokumoto FT, Teruki Miyake, Masashi Hirooka Masanori Abe TK et al. Upregulated palmitic acid absorption with altered intestinal transporters in non-alcoholic steatohepatitis (NASH). Hepatology 2016; 64.
4. du Plessis, J., van Pelt, J., Korf, H., et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 635–648 e14.
5. Montano-Loza, Aldo J., Michael Sawyer, J.M.-J., Vickie Baracos, N.M.K., High visceral adipose tissue is associated with hepatocellular carcinoma in cirrhosis and increased risk of recurrence after liver transplantation. Hepatology, 64, 2016, A126.
6. Balakrishnan M et al., Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association; 2017.
7. Fracanzani AL et al., Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association; 2017.
8. Ye Eun Kwak, A.D., Lim, Joseph K., Central body fat distribution is associated with increased risk of nonalcoholic fatty liver disease in lean individuals: a population based study from the national health and nutrition examination survey. Hepatology, 64, 2016, 549A.
9. Spadoni, I., Zagato, E., Bertocchi, A., et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science 350 (2015), 830–834.
10. Wiest, R., Rath, H.C., Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol 17 (2003), 397–425.
11. Delacroix, D.L., Hodgson, H.J., McPherson, A., Dive, C., Vaerman, J.P., Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J Clin Invest 70 (1982), 230–241.
12. Macpherson, A.J., Slack, E., The functional interactions of commensal bacteria with intestinal secretory IgA. Curr Opin Gastroenterol 23 (2007), 673–678.
13. Bollinger, R.R., Everett, M.L., Palestrant, D., Love, S.D., Lin, S.S., Parker, W., Human secretory immunoglobulin A may contribute to biofilm formation in the gut. Immunology 109 (2003), 580–587.
14. Palm, N.W., de Zoete, M.R., Cullen, T.W., et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158 (2014), 1000–1010.
15. Moro-Sibilot, L., Blanc, P., Taillardet, M., et al. Mouse and human liver contain immunoglobulin a-secreting cells originating from Peyer's patches and directed against intestinal antigens. Gastroenterology 151 (2016), 311–323.
16. Fukuda, Y., Imoto, M., Hayakawa, T., Serum levels of secretory immunoglobulin A in liver disease. Am J Gastroenterol 80 (1985), 237–241.
17. van de Wiel, A., Schuurman, H.J., van Riessen, D., et al. Characteristics of IgA deposits in liver and skin of patients with liver disease. Am J Clin Pathol 86 (1986), 724–730.
18. Ridlon, J.M., Harris, S.C., Bhowmik, S., Kang, D.J., Hylemon, P.B., Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7 (2016), 22–39.
19. Yoshimoto, S., Loo, T.M., Atarashi, K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
20. Bourzac, K., Microbiome: the bacterial tightrope. Nature 516 (2014), S14–S16.
21. Wiest, R., Lawson, M., Geuking, M., Pathological bacterial translocation in liver cirrhosis. J Hepatol 60 (2014), 197–209.
22. Ridlon, J.M., Alves, J.M., Hylemon, P.B., Bajaj, J.S., Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 4 (2013), 382–387.
23. Tilg, H., Cani, P.D., Mayer, E.A., Gut microbiome and liver diseases. Gut, 2016.
24. Boursier, J., Mueller, O., Barret, M., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63 (2016), 764–775.
25. Llopis, M., Cassard, A.M., Wrzosek, L., et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65 (2016), 830–839.
26. Puneet Puri, Faridoddin Mirshahi, Suthat Liangpunsakul, Naga P. Chalasani DWC, Vijay Shah, Patrick S. Kamath et al. Alcoholic hepatitis and disease severity are associated with distinct shifts in fecal microbial ecology. Hepatology 2016; 64: A1212.
27. Sabino, J., Vieira-Silva, S., Machiels, K., et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65 (2016), 1681–1689.
28. Bajaj, J.S., Betrapally, N.S., Gillevet, P.M., Decompensated cirrhosis and microbiome interpretation. Nature 525 (2015), E1–E2.
29. Bajaj, J.S., Betrapally, N.S., Hylemon, P.B., et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 62 (2015), 1260–1271.
30. Lachar, J., Bajaj, J.S., Changes in the microbiome in cirrhosis and relationship to complications: hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis. Semin Liver Dis 36 (2016), 327–330.
31. Noriho Iida, E.M., Kaneko, Shuichi, Inflammatory and carcinogenic features of gut microbiota in hepatocellular carcinoma patients. Hepatology, 64, 2016.
32. Puneet Puri FM, Kalyani Daita, Robert Vincent, Suthat Liangpunsakul, David W., Crabb, Patrick S. Kamath et al. Quantitative and qualitative changes in the circulating microbiome are associated with the development and severity of alcoholic hepatitis. Hepatology 2016; 64.
33. Raj, Ashok S., Shanahan, Erin, Fletcher, Linda M., Cuong, Tran, Bhat, Purnima, Morrison, Mark, Increased small intestinal permeability in chronic liver disease is associated with reduced abundance of Faecalibacterium prausnitzii in the terminal ileum mucosa. Hepatology, 64, 2016, A687.
34. Krag A. GALAXY: Gut-and-liver axis in alcoholic liver fibrosis. EU-Horizon-20/20; livergalaxyeu.
35. Bajaj, J.S., Fagan, A., Sikaroodi, M., et al. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. Liver Transplant, 2017.
36. Mathurin Philippe M, University Hospital, Lille; NCT02281929. Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone (AntibioCor).
37. Perttu Sahlman M, Helsinki UHo. Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis. NCT02326103; 2017.
38. Rahimpour, S., Nasiri-Toosi, M., Khalili, H., Ebrahimi-Daryani, N., Nouri-Taromlou, M.K., Azizi, Z., A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis 25 (2016), 457–464.
39. Ochsner Medical Center NO, Louisiana, United States, 70121, Contact: Shamita Shah M–ssoo. Vancomycin treatment in recurrent PSC in liver transplant patients. NCT03046901; 2017.
40. Etienne Sokal M, PhD, Saint-Luc Cu. Overlap syndrome and PSC: evaluating role of gut microflora and its identification with antibiotics in children. NCT03069976; 2017.
41. Jiang, Z.D., Ke, S., Dupont, H.L., Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 35 (2010), 278–281.
42. Kang, D.J., Kakiyama, G., Betrapally, N.S., et al. Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin Transl Gastroenterol, 7, 2016, e187.
43. Gangarapu, V., Ince, A.T., Baysal, B., et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 27 (2015), 840–845.
44. Bass, N.M., Mullen, K.D., Sanyal, A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362 (2010), 1071–1081.
45. Ahluwalia, V., Wade, J.B., Heuman, D.M., et al. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis 29 (2014), 1017–1025.
46. Bajaj, J.S., Heuman, D.M., Wade, J.B., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140 (2011), 478–487 e1.
47. Bajaj, J.S., Heuman, D.M., Sanyal, A.J., et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One, 8, 2013, e60042.
48. Dupont, H.L.H.T., Sanyal, A.J., Wolf, R.A., Mullen, K.D., Genomic characterization of stool microbiota with rifaximin monotherapy versus lactulose combination therapy for prevention of overt hepatic encephalopathy (HE) recurrence. Hepatology 63 (2016), 720A–721A.
49. Soldi, S., Vasileiadis, S., Uggeri, F., et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol 8 (2015), 309–325.
50. Bajaj, J.S.F.S., Chalasani, N., Diaz, E., Kayali, Z., Kang, R., Bortey, E., et al. Oral rifaximin soluble solid dispersion immediate-release 40 mg prevents development of cirrhosis-related complications: a phase 2, randomized, multicenter, double-blind, placebo-controlled trial. Hepatology, 63, 2016, 1027A.
51. Hospital Universitari Vall d‘Hebron Research Institute N. Effects of rifaximin in patients with acute alcoholic hepatitis (RIFA-AAH).
52. Mansoura University E, NCT02884037. Rifaximin modify the pathogenesis of non-alcoholic-fatty-liver-disease (NAFLD).
53. Shawcross DKsCHNT, NCT02019784. Randomised controlled trial of mechanistic effects of rifaximin in cirrhosis and chronic hepatic encephalopathy (RIFSYS).
54. Wei-Fen Xie MDoG, Changzheng Hospital, Second Military Medical University, Shanghai. Rifaximin reduces the complications of decompensated cirrhosis: a randomized controlled trial. NCT02190357; 2017.
55. Nina Kimer M, Department of Gastroenterology CUHH. Intestinal decontamination with rifaximin. The inflammatory and circulatory state in patients with cirrhosis. NCT01769040; 2016.
56. Christophe Bureau MP, University Hospital T. Rifaximin vs placebo for the prevention of encephalopathy in patients treated by TIPS (PRPET). NCT02016196; 2017.
57. Thierry THEVENOT M, PhD. Two strategies of primary prophylaxis of spontaneous bacterial peritonitis in severe cirrhotic patients with ascites (ProPILARifax). NCT03069131; 2016.
58. Shiyao CHEN MD, Zhongshan Hospital FU, Shanghai. Rifaximin in patients with gastroesophageal variceal bleeding (RFXM). NCT02991612; 2016.
59. Enoch Bortey PD, Valeant pharmaceuticals international I. Efficacy, safety, and pharmacokinetics of rifaximin in subjects with severe hepatic impairment and hepatic encephalopathy. NCT01846663; 2017.
60. Nasser H Mousa M, Mansoura, Egypt rifaximin modify the pathogenesis of non-alcoholic fatty liver disease (NAFLD). NCT02884037; 2017.
61. RWTH Aachen University; Aachen G, 52074, Contact: Ulf Neumann P, MD uneumann@ukaachen.de Administration of rifaximin to improve liver regeneration and outcome following major liver resection (ARROW). NCT02555293; 2017.
62. Fernandez, J., Tandon, P., Mensa, J., Garcia-Tsao, G., Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology 63 (2016), 2019–2031.
63. Letexier, D., Diraison, F., Beylot, M., Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr 77 (2003), 559–564.
64. Tarantino, G., Finelli, C., Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol 10 (2015), 889–902.
65. Lambert, J.E., Parnell, J.A., Eksteen, B., et al. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol, 15, 2015, 169.
66. Yaakov Maor KMC. Prebiotics in patients with non-alcoholic liver disease. NCT02642172; 2017.
67. Saez-Lara, M.J., Robles-Sanchez, C., Ruiz-Ojeda, F.J., Plaza-Diaz, J., Gil, A., Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci, 17, 2016.
68. Ma, Y.Y., Li, L., Yu, C.H., Shen, Z., Chen, L.H., Li, Y.M., Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 19 (2013), 6911–6918.
69. Sepideh, A., Karim, P., Hossein, A., et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr 35 (2016), 500–505.
70. Ajay K. Duseja, Manu Mehta, Shruti, Chhabra S, Satyavati Rana, Ashim Das, Siddhartha, Datta Gupta et al. Probiotic VSL#3 improves liver histology in patients with nonalcoholic fatty liver disease – A proof of concept study. Hepatology 2016; 64: 596A.
71. Shiri Sherf Dagan, Shira Zelber-Sagi, Gili Zilberman-Schapira, Muriel Webb, Andrei Keidar, Asnat, Raziel et al;. Probiotics do not improve hepatic outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized clinical trial. Hepatology 2016; 64.
72. David W. Orr, Rinki Murphy. Probiotic supplementation after very low calorie diet does not aid improvement of the metabolic syndrome or maintenance of weight loss post liver transplant. a randomised double-blind placebo controlled trial. Hepatology 2016; 64: 113A.
73. Maor KMC, Israel, NCT 02642172. Prebiotics in patients with non-alcoholic liver disease. 2016.
74. Reimer R.; University of Calgary CIoHRN. Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease; 2016.
75. CD Byrne NIfHR, UK, NCT 0168064. Investigation of synbiotic treatment in NAFLD (INSYTE); 2016.
76. G.Z. Port FUoHSoPA, NCT02764047. Probiotics in the treatment of NAFLD; 2016.
77. ANgel Gil UG, Spain, NCT 02972567. Evaluation of the effects of L. Reuteri strain on markers of inflammation, cardiovascular risk and fatty liver disease (PROSIR); 2016.
78. Hill, C., Scott, K., Klaenhammer, T.R., Quigley, E., Sanders, M.E., Probiotic nomenclature matters. Gut Microbes 7 (2016), 1–2.
79. Han, S.H., Suk, K.T., Kim, D.J., et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol 27 (2015), 1300–1306.
80. Ki Tae Suk CSHH, NCT02335632. Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis. NCT02335632; 2016.
81. Vleggaar, F.P., Monkelbaan, J.F., van Erpecum, K.J., Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 20 (2008), 688–692.
82. Vrieze, A., Van Nood, E., Holleman, F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (2012), 913–916 e7.
83. Saab, S., Suraweera, D., Au, J., Saab, E.G., Alper, T.S., Tong, M.J., Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int 36 (2016), 986–993.
84. Agrawal, A., Sharma, B.C., Sharma, P., Sarin, S.K., Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 107 (2012), 1043–1050.
85. Dhiman, R.K., Rana, B., Agrawal, S., et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147 (2014), 1327–1337 e3.
86. Horvath, A., Leber, B., Schmerboeck, B., et al. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther 44 (2016), 926–935.
87. Liu, Q., Duan, Z.P., Ha, D.K., Bengmark, S., Kurtovic, J., Riordan, S.M., Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39 (2004), 1441–1449.
88. Jayakumar, S., Carbonneau, M., Hotte, N., et al. VSL#3 (R) probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int 33 (2013), 1470–1477.
89. Gupta, N., Kumar, A., Sharma, P., Garg, V., Sharma, B.C., Sarin, S.K., Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int 33 (2013), 1148–1157.
90. Sawas, T., Al Halabi, S., Hernaez, R., Carey, W.D., Cho, W.K., Patients receiving prebiotics and probiotics before liver transplantation develop fewer infections than controls: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 13 (2015), 1567–1574.
91. Grat M et al., Clinical nutrition (Edinburgh, Scotland); 2017.
92. Cleber Kruel DHdCdPA. Effect of Synbiotic on Postoperative Complications After Liver Transplantation. NCT02938871; 2016.
93. Huet E.; University Hopsital Rouen N. Influence of probiotics administration before liver resection in liver disease (LIPROCES). NCT02021253; 2016.
94. Meighani, Alireza, Salgia, Reena, Successful outcomes of fecal microbiota transplantation in patients with chronic liver disease. Hepatology, 64, 2016, 1017A.
95. Bajaj J.S. et al., Hepatology; 2017.
96. Cyriac A. Philips, Apurva Pande, Kapil, D. Jamwal, Guresh Kumar, Shvetank, Sharma, Rakhi Maiwall, et al. Fecal microbiota transplantation (FMT) improves outcome and survival in steroid ineligible severe alcoholic hepatitis–A randomized control trial (NCT 02458079). Hepatology 2016; 64: 706A.
97. Jasmohan S. Bajaj, Andrew Fagan, Edith A. Gavis, Eric Liu, Jane Cox, Raffi Kheradman, et al. Fecal microbiota transplant using a precision medicine approach is safe, associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy. ILC2017-RS-2127; 2017.
98. Abbo L. FMT for MDRO Colonization in Liver Transplantation (FMT). NihGov 2016; NCT02816437.
99. Shawcross D. Trial of Faecal Microbiota Transplantation in Cirrhosis (PROFIT). NihGov 2016; NCT02862249.
100. Institute of Liver and Biliary Sciences I. Fecal Microbiota Therapy versus Standard Therapy in decompensated NASH related Cirrhosis: A Randomized Controlled Trial. NihGov 2016; NCT02868164.
101. Silverman M. Transplantation of microbes for treatment of metabolic syndrome and NAFLD (FMT). NihGov 2016; NCT02496390.
102. Kittichai Promrat L. Fecal microbiota transplantation (FMT) in nonalcoholic steatohepatitis (NASH). A Pilot Study. NihGov 2016; NCT02469272.
103. Joshua Korzenik BaWH. Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. NihGov 2016; NCT 02424175.
104. Sterns, R.H., Grieff, M., Bernstein, P.L., Treatment of hyperkalemia: something old, something new. Kidney Int 89 (2016), 546–554.
105. Di Padova, C., Tritapepe, R., Rovagnati, P., Rossetti, S., Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 6 (1984), 773–776.
106. Schulman, G., Berl, T., Beck, G.J., et al. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrol, 17, 2016, 141.
107. Bosoi, C.R., Parent-Robitaille, C., Anderson, K., Tremblay, M., Rose, C.F., AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 53 (2011), 1995–2002.
108. Bajaj, J.S.S.M., Chojkier, M., Balart, L., Sherker, A.H., VEmuru, R., et al. AST-120 in covert hepatic encephalopathy: Results of the ASTUTE trial. J Hepatol, 58, 2013, S84.
109. McNaughtan J SJ, Mouralidarane A, Sandeman S, Howell C, Kozynchenko O, Tennison S, Mikhalovsky S, Davies N, Oben J, Mookerjee R, Jalan R. Biological effects of oral nanoporous carbon in bile duct ligated rats. Gut 2012; 61(A124).
110. Macnaughtan J, Sawhney R, Oben J, Davies N, Mookerjee R, et al. Oral carbon therapy is associated with a selective modulation of the microbiome in cirrhotic rats which is associated with a significant reduction in inflammatory activation. Gut 2015; 64:(PTH-095).
111. Macnaughtan J, Mouralidarane A, Saneman S, Howell C, Mikhalovsky S, Kozynchenko O, et al. Effects of oral nanoporous carbon therapy in leptin null mice as a model of non-alcoholic steatohepatitis. Gut 2012; 61(A125).
112. Jalan R. DOSE ESCALATING STUDY OF THE SAFETY OF YAQ-001 IN PATIENTS WITH CIRRHOSIS. carbaliveeu; 2017.
113. Wahlstrom, A., Sayin, S.I., Marschall, H.U., Backhed, F., Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24 (2016), 41–50.
114. van Nierop, F.S., Scheltema, M.J., Eggink, H.M., et al. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol, 2016.
115. Zhu, Y., Li, F., Guo, G.L., Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol Res 63 (2011), 259–265.
116. Wahlstrom, A., Al-Dury, S., Casselbrant, A., Bergentall, M., Stahlman, M., Olsson, L., et al. Decreased intestinal glucose absorption in healthy volunteers treated with the FXR agonist obeticholic acid. Hepatology, 64, 2016, 185.
117. Nevens, F., Andreone, P., Mazzella, G., et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375 (2016), 631–643.
118. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (London, England) 2015; 385(9972): 956–65.
119. Nicholes, K., Guillet, S., Tomlinson, E., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160 (2002), 2295–2307.
120. Cathi Sciacca Vice President Clinical Operations IPI. Randomized global phase 3 study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment (REGENERATE). NCT02548351; 2017.
121. Chalasani NP, (NIAAA) NIoAAaA, Pharmaceuticals I. Trial of obeticholic acid in patients with moderately severe alcoholic hepatitis (AH) (TREAT). NCT02039219; 2017.
122. Pharmaceuticals I. Obeticholic Acid (OCA) in primary sclerosing cholangitis (PSC) (AESOP). NCT02177136; 2017.
123. Stefan Traussnigg CK, Emina Halilbasic, Christian Rechling HH, Petra E. Steindl-Munda, Ghazaleh Gouya MW, Martin Hornberger, et al. Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease (NAFLD). Hepatology 2016; 64:536 A.
124. Dorothy French JTL, Henry Liu, Erik G. Huntzicker, Constantine S. Djedjos, Robert P. Myers, William, Watkins;. Pharmacodynamic effects of the non-steroidal farnesoid X receptor (FXR) agonist GS-9674 in high fat, high cholesterol diet fed cynomolgus monkeys. Hepatology 2016; 64: 71A.
125. Liles, J.K., Karnik, S., Hambruch, E., Kremoser, C., Birkel, M., Watkins, W.J., et al. FxR agonism by GS-9674 decreases steatosis and fibrosis in a murine model of NASH. J Hepatol, 64, 2016.
126. Schwabl PH, Supper, P, Burnet, M, Peck-Radovasvljevic, M, Reiberger, T et al. The non-steroidal FxR-agonist Gs-9674 reduces fibrosis and ameliorates portal hypertension in a rat Nash-model. J Hepatol 2016; 64(S165–S166).
127. Constantine S. Djedjos BK, Andrew Billin, John Gosink, Qinghua Song RS, Krystyna Grycz, Jonna Weston, Mani Subramanian WW, Robert P. Myers;. Pharmacodynamic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers. Hepatology 2016; 64:543A.
128. Brian Kirby CSD, Joanne Birkebak, Qinghua, Song KG, Jonna Weston, Mani Subramanian, William, Watkins RPM, Anita Mathias. Evaluation of the Safety and Pharmacokinetic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers. Hepatology 2016; 64: 574A.
129. Rob Myers MGS. Study in Healthy Volunteers to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GS-9674, and the effect of food on GS-9674 pharmacokinetics and pharmacodynamics. NCT02654002; 2016.
130. Sciences GSDG. Evaluating the safety, tolerability, and efficacy of GS-9674 in participants with nonalcoholic steatohepatitis (NASH). NCT02854605; 2017.
131. Sciences GSDG. safety, tolerability, and efficacy of selonsertib, GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis (NASH). NCT02781584; 2017.
132. Rohit Loomba EL, Parvez S. Mantry, Saumya Jayakumar, Stephen H. Caldwell HA, Anna Mae Diehl, Constantine S. Djedjos CJ, et al. Afdhal10 MRC. GS-4997, an Inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): a randomized, phase 2 trial. Hepatology 2016; 64(LB-3).
133. Xiaoxin Wang AL, Suman Ranjit, Dong Wang, Yuhuan Luo DJO, James McManaman, et al. The FXR/TGR5 dual agonist INT-767 prevents and reverses Western diet-induced NASH and modulates major lipid metabolic pathways in mice. Hepatology 2016; 64(A1528).
134. Roth J, Skovgaard S, Rigbolt K, Jelsing J, Vrang N, Young M. The FXR/TGR5 dual agonist INT-767 reduces NAFLD activity score and fibrosis stage and improves plasma and hepatic lipid profiles in the GUBRA-AMLN mouse model of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis (NASH). Hepatology 2016; 64(752 A).
135. Guo, C., Chen, W.D., Wang, Y.D., TGR5, not only a metabolic regulator. Front Physiol, 7, 2016, 646.
136. van Nierop, F.S., Scheltema, M.J., Eggink, H.M., et al. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol 5 (2017), 224–233.
137. Pharmaceuticals N. Safety, Tolerability and Efficacy Study of 12 Weeks LJN452 Treatment in NASH Patients (FLIGHT-FXR). NCT02855164; 2017.
138. Michael K. Badman1 SD, Bryan Laffitte, Marc Decristofaro, TsuHan Lin JC, John F. Reilly, Lloyd Klickstein. First-in-Human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects. Hepatology 2016; 64: 16A.
139. Melissa Palmer LJ, Debra Silberg, Caleb Bliss, Patrick, Martin;. Volixibat, a minimally absorbed, oral, apical sodium-dependent bile acid transporter (ASBT) inhibitor, increases bile acid excretion, reduces serum lipids, is safe and tolerable in overweight and obese subjects, a population characteristic of NASH. Hepatology 2016; 64: 574A.
140. Patrick Martin MS. Safety and Tolerability Study of SHP626 in Overweight and Obese Adults. NCT02287779; 2017.
141. Shire SP. Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH). NCT02787304; 2017.
142. Safadi, R., Konikoff, F.M., Mahamid, M., et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12 (2014), 2085–2091 e1.
143. Vlad Ratziu M, PhD, Paris. PoHatUPeMCatHPSMUi. A clinical trial to evaluate the efficacy and safety of two aramchol doses versus placebo in patients with NASH (Aramchol_005). NCT02279524; 2017.
144. Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., Moschetta, A., Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7 (2014), 12–18.
145. Fang, S., Suh, J.M., Reilly, S.M., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21 (2015), 159–165.
146. Verbeke, L., Farre, R., Verbinnen, B., et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 185 (2015), 409–419.
147. Verbeke, L., Mannaerts, I., Schierwagen, R., et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep, 6, 2016, 33453.
148. Ubeda, M., Lario, M., Munoz, L., et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 64 (2016), 1049–1057.
149. Inagaki, T., Moschetta, A., Lee, Y.K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103 (2006), 3920–3925.
150. Gadaleta, R.M., van Erpecum, K.J., Oldenburg, B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
151. Tolbol SSV, Knudsen, HK Erichsen, MN Kristiansen, J Jelsing, N Vrang, M Feigh. The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed nonalcoholic steatohepatitis (NASH). Hepatology 64 2016; 64(782A).
152. de Mesquita, F.C., et al. Sci Rep, 7, 2017, 3255.
153. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England) 2016; 387: 679–90.
154. Wolfgang E. Schmidt PDR-UB. Effects of exenatide (Byetta®) on liver function in patients with nonalcoholic steatohepatitis (NASH). NCT01208649; 2010.
155. Joan Khoo Joo Ching CSC, Changi General Hospital. Comparing effects of liraglutide and bariatric surgery on weight loss, liver function, body composition, insulin resistance, endothelial function and biomarkers of non-alcoholic steatohepatitis (NASH) in obese asian adults (CGH-LiNASH). NCT02654665; 2016.
156. Jianping Weng D, Third affiliated hospital, Sun Yat-Sen University. Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects (LIGHT-ON). NCT02147925; 2017.
157. Fudan University C. Exenatide compared with insulin glargine to change liver fat content in type 2 diabetes. NCT02303730; 2016.
158. BV. Effect of liraglutide on fatty liver content and lipoprotein metabolism (LIRA-NAFLD/LIP). NCT02721888; 2016.
159. Cui, J., Philo, L., Nguyen, P., et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol 65 (2016), 369–376.
160. Unzueta A, Portillo-Sanchez, P. Biernacki, D. Suman, A. Weber, M. Cusi K. Postprandial hyperglycemia and hyperinsulinemia are associated with advanced fibrosis in patients with diabetes and NASH. Hepatology 2016; 64: 35.
161. Knop, F.K., Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. Am J Physiol Endocrinol Metab 299 (2010), E10–E13.
162. Ohki, T., Isogawa, A., Toda, N., Tagawa, K., Clin Drug Invest 36 (2016), 313–319.
163. Shireene Vethakkan UoM. he Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes. NCT02964715; 2016.
164. e.V TDDF. Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes (EmLiFa). NCT02637973; 2017.
165. Arab, J.P., Karpen, S.J., Dawson, P.A., Arrese, M., Trauner, M., Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 65 (2017), 350–362.
166. Zhou, M., Luo, J., Chen, M., et al. Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J Hepatol 66 (2017), 1182–1192.
167. Lei Ling MZ, Marc Learned, Stephen J. Rossi, Hui Tian, DePaoli; AM. Human FGF19 but not NGM282, an Engineered variant of FGF19, causes hepatocellular carcinoma (HCC) in a diet-induced mouse model of non-alcoholic steatohepatitis (NASH). Hepatology 2016; 64(LB-19).
168. Mayo MJ, Roberts SK, Arnold H, Hassanein TIB, Leggett A, Bate JP, et al Thompson. NGM282, A novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology 2015; 62; 1: 106.
169. Stephen J Rossi PNB, Inc., Phase 2 study of NGM282 in patients with primary sclerosing cholangitis. NCT02704364; 2016.
170. Stephen J Rossi PNB, Inc. study of NGM282 in patients with nonalcoholic steatohepatitis. NCT02443116; 2016.
171. Krupinski NM, Kozhich A, Chiney M, Morin P, Christian R. Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2016; 64: 1501.
172. Charles ED, Hompesch M, Luo Y, Wu, CK Christian R. A phase 1 study of BMS-986036 (Pegylated FGF21) in Healthy Obese Subjects. Hepatology 2016; 64: 1082.
173. Wu CKEDC, A. Bui, R. Christian, M. Abu Tarif. Phase 1 study of BMS-986171 (Pegylated FGF21) in Healthy Obese Subjects. Hepatology 2016; 64(564A): 1118.
174. E. D. Charles BAT, Y. Luo, C. K. Wu, R. Christian;. A Phase 2 Study of BMS-986036 (Pegylated FGF21) in Obese Adults with Type 2 Diabetes and a High Prevalence of Fatty Liver. Hepatology 2016; 64(17A): 33.
175. Squibb r-M. A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH). NCT02413372; 2017.
176. Jun Hwan Kim HNH, Hyun Ho Choi, Dohoon Kim, Tae Wang Kim SL, Minji Seo, Mi Kyeong Ju, Ju-Young Park BHC, et al. YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models. Hepatology 2016; 64.
177. Michelle L. Beaton JG, Christopher Rhodes, Lutz Jermutus, Anish Konkar JT. MEDI0382, a dual GLP-1/glucagon receptor agonist, exerts beneficial effects on mitochondrial content and function in primary hepatocytes from lean and NASH mice. Hepatology 2016; 64.
178. J. Trevaskis MLB, M. Bednarek, D. C. Hornigold, J. Naylor, A. Collinson, S. Skovgaard Veidal, A. Nygaard Madsen, P. Ambery, S. Henderson, M. P. Coghlan, J. Grimsby, C. Rhodes, L. Jermutus, A. Konkar. The Dual Glucagon-Like Peptide-1 (GLP-1)/Glucagon Receptor Agonist MEDI0382 Improves Metabolic and Hepatic Indices of NASH in Mice. Hepatology 2016; 64: 1505.
179. Dietrich, P., Moleda, L., Kees, F., et al. Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: impact of exogenous neuropeptide Y. J Hepatol 58 (2013), 254–261.
180. Henriksen, J.H., Moller, S., Ring-Larsen, H., Christensen, N.J., The sympathetic nervous system in liver disease. J Hepatol 29 (1998), 328–341.
181. de Franchis, R., Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63 (2015), 743–752.
182. Perez-Paramo, M., Munoz, J., Albillos, A., et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31 (2000), 43–48.
183. Reiberger, T., Ferlitsch, A., Payer, B.A., et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58 (2013), 911–921.
184. Thiele, M., Wiest, R., Gluud, L.L., Albillos, A., Krag, A., Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?. Med Hypotheses 81 (2013), 871–874.
185. Mookerjee, R.P., Pavesi, M., Thomsen, K.L., et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol 64 (2016), 574–582.
186. Thiele, M., Albillos, A., Abazi, R., Wiest, R., Gluud, L.L., Krag, A., Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int 35 (2015), 2009–2016.
187. Sigala, B., McKee, C., Soeda, J., et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One, 8, 2013, e72928.
188. von Montfort, C., Beier, J.I., Guo, L., Kaiser, J.P., Arteel, G.E., Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice. Am J Physiol Gastrointest Liver Physiol 294 (2008), G1227–G1234.
189. Browning, K.N., Verheijden, S., Boeckxstaens, G.E., The vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology 152 (2016), 730–744.
190. Cheadle, G.A., Costantini, T.W., Bansal, V., Eliceiri, B.P., Coimbra, R., Cholinergic signaling in the gut: a novel mechanism of barrier protection through activation of enteric glia cells. Surg Infect 15 (2014), 387–393.
191. Bockx, I., Verdrengh, K., Vander Elst, I., et al. High-frequency vagus nerve stimulation improves portal hypertension in cirrhotic rats. Gut 61 (2012), 604–612.
192. Cynthia Aranow M, Investigator, Northwell Health. Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway (TEACAP). NCT02910973; 2016.
193. Geert D'Haens MD, Ph.D., (AMC-UvA) AMC-UvA. Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease. NCT02951650; 2016.
194. Radwan KASSIR M, Etienne CdS. Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery (OBESITE). NCT02648191; 2016.
195. Madrid, A.M., Hurtado, C., Venegas, M., Cumsille, F., Defilippi, C., Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 96 (2001), 1251–1255.
196. Garcia-Tsao, G., Prokinetics reduce bacterial translocation in cirrhosis: will sweeping the gut keep the fluid clean?. Gastroenterology 120 (2001), 314–316.
197. Tsuchida, Y., Hatao, F., Fujisawa, M., et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via alpha7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut 60 (2011), 638–647.
198. Takaki, M., Goto, K., Kawahara, I., The 5-hydroxytryptamine 4 receptor agonist-induced actions and enteric neurogenesis in the gut. J Neurogastroenterol Motil 20 (2014), 17–30.
199. Yano, J.M., Yu, K., Donaldson, G.P., et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161 (2015), 264–276.
200. Jang, J.H., Rickenbacher, A., Humar, B., et al. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation. Hepatology 56 (2012), 209–218.
201. Nocito, A., Dahm, F., Jochum, W., et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 133 (2007), 608–618.
202. Mann, D.A., Oakley, F., Serotonin paracrine signaling in tissue fibrosis. Biochim Biophys Acta 1832 (2013), 905–910.
203. Ebrahimkhani, M.R., Oakley, F., Murphy, L.B., et al. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat Med 17 (2011), 1668–1673.
204. Starlinger, P., Assinger, A., Haegele, S., et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology 60 (2014), 257–266.
205. Patrick Starlinger M, PhD, Vienna MU. Platelets in Liver Regeneration. NCT02113059; 2016.
206. Soll, C., Jang, J.H., Riener, M.O., et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 51 (2010), 1244–1254.
207. Fatima, S., Shi, X., Lin, Z., et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing beta-catenin. Mol Oncol 10 (2016), 195–212.
208. Padickakudy RH, S.; Offensperger, F.; Pereyra, D.; Ohlberger, L.; Assinger, A.; Fleischmann, E.; Brostjan, C.; Gruenberger, T.; Starlinger, P.;. Intra-platelet serotonin and oncologic outcome. ECMO 2015; 51, Suppl 3: S43–S4.
209. Fried, M., Yumuk, V., Oppert, J.M., et al. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts 6 (2013), 449–468.
210. Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
211. Zhang, H., DiBaise, J.K., Zuccolo, A., et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106 (2009), 2365–2370.
212. Catoi, A.F., Parvu, A., Muresan, A., Busetto, L., Metabolic mechanisms in obesity and type 2 diabetes: insights from bariatric/metabolic surgery. Obes Facts 8 (2015), 350–363.
213. Lassailly G, Caiazzo R, Buob D, et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology 2015; 149(2): 379–88; quiz e15–6.
214. Marchesi, J.R., Adams, D.H., Fava, F., et al. The gut microbiota and host health: a new clinical frontier. Gut 65 (2016), 330–339.
215. Gerhard, G.S., Still, C.D., DiStefano, J.K., High false-negative rate for nonalcoholic steatohepatitis in extreme obesity. Gastroenterology 150 (2016), 283–284.
216. Manco M et al., The Journal of pediatrics 180, 31–37.e32 (2017).
217. Barros F; Ministry of Health Brazil N. Impact of Bariatric Surgery on the Evolution of Nonalcoholic Fatty Liver Disease: a Comparative Clinical Trial Between Sleeve Gastrectomy and Gastric Bypass. 2016. NCT02394353.
218. NCT02390973 LB. Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION). 2016.
219. Vi Nguyen JL, Paul Cordero, Gilberto Alejandro S. Cuevas, Mai Khatib JAO. Intra-Gastric Balloon (IGB): an endoscopic treatment option for obesity and NAFLD. Hepatology 2016; 64: A1125.
220. Oranit Cohen-Ezra GS-L, Alon Lang, Yeroham Kleinbaum YI, Sima Katsherginsky, Keren, Tsaraf ZBA. Improvement in non-invasive hepatic parameters of nonalcoholic fatty liver disease in obese uncontrolled type 2 diabetes mellitus patients who underwent endoscopic duodenal-jejunal bypass liner (Endobarrier) implantation. Hepatology 2016; 64.
221. van Baar ACG, Academic Medical Center, Amsterdam, the Netherlands, J. Devière DoG, Erasme University Hospital, Brussels, Belgium, G. Costamagna DoDE, Policlinico Gemelli, Catholic University of Rome, Rome, Italy, et al. A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients. Hepatology 2016; 64(LB-34): A557.
222. Robert Dobbins M, PhD, Inc C. Safety and efficacy of solithromycin in the treatment of nonalcoholic steatohepatitis without cirrhosis. NCT02510599; 2017.
223. Mehmet Mutlu M, Karadeniz Technical University. Effects of probiotics on neonatal hyperbilirubinemia. NCT02807246; 2016.
224. Graz MUo. Influence of Probiotics on Infections in Cirrhosis (PIC). NCT01607528; 2016.
225. Wojciech M Marlicz MD, Ph.D. Pomeranian medical university szczecin. evaluation of probiotics in the treatment of portal hypertension. NCT00831337; 2016.
226. Sciences G. Pharmacokinetics and pharmacodynamics of GS-9674 in adults with normal and impaired hepatic function. NCT02808312; 2017.
227. Director GS, Sciences G. Safety, Tolerability, and efficacy of GS-9674 in adults with primary sclerosing cholangitis without cirrhosis (PSC-Phase 2). NCT02943460; 2017.
228. Kenneth Cusi MD, University of Florida. Adding exenatide to insulin therapy for patients with type 2 diabetes and non-alcoholic fatty liver disease. NCT01006889; 2016.
229. Melanie Cree-Green UC. Liver and fat regulation in overweight adolescent girls (APPLE). NCT02157974; 2017.